Evaluation of safety and pharmacokinetic parameters of the PTI5803 product
This clinical trial is looking at a new potential medicine called PTI5803, which might one day help people with epilepsy. It's an early-stage study, often called a Phase 1 trial. The main goals are to carefully check if the medicine is safe for people to take and to understand how the body uses and gets rid of it. This includes looking at things like how quickly it's absorbed and how long it stays in the system. Because it's so early, the study is focused on gathering basic information in healthy adult volunteers rather than treating epilepsy directly. This vital first step helps researchers decide if the medicine is promising enough to continue with further studies.
At a glance
What is this study about?
Imagine scientists are trying to build a new type of bicycle. Before they try to race it, they need to make sure the wheels won't fall off and that it's comfortable to ride. This study is a bit like that – it's an early check-up for a new medicine called PTI5803, which is being developed for people with epilepsy.
The main aim of this study is to see if PTI5803 is safe for people to take. Scientists also want to understand what happens to the medicine once it's in your body – how much is absorbed, how long it stays around, and how the body gets rid of it. This information is really important because it helps them work out the right dose for future studies and whether the medicine has the potential to help people with epilepsy.
This kind of study, called a Phase 1 or Human Pharmacology study, is usually the very first time a new medicine is given to people. It's not designed to treat epilepsy yet, but rather to gather essential safety information and understand how the medicine behaves in the body before it can be tested in larger groups of people who actually have epilepsy.
Key takeaways
- This is an early-stage study for a new epilepsy medicine called PTI5803.
- The main goals are to check the medicine's safety and how it works in the body.
- It's open to healthy adults aged 18 and over, both men and women.
- Participation involves clinic visits, possibly overnight stays, and close monitoring.
- You won't be treated for epilepsy in this study; it's a safety check.
- You can stop participating at any time.
Who may be eligible?
To join this study, you need to be an adult, aged 18 years or older. There isn't an upper age limit, so people of many different ages can take part as long as they meet the other health requirements.
Both men and women are welcome to participate in this research. The study aims to gather information from a broad group of people to understand how the medicine behaves generally.
Since this is an early safety study, volunteers will likely need to be in good overall health, without any significant ongoing medical conditions. The research team will do thorough checks to make sure it's safe for you to take part.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you generally feel healthy?
- Are you comfortable with regular hospital or clinic visits?
- Are you willing to take a new, untested medicine?
- Are you willing to have blood tests?
- Are you able to commit to the duration of the study?
What does participation involve?
If you decide to take part in this study, you would likely have an initial screening visit where doctors would check your general health, possibly including blood tests, heart checks, and a physical exam. If you are suitable, you would then receive the study medicine, PTI5803. This medicine might be given once or multiple times over a period, depending on the study's design.
You would need to attend several visits to the clinic, possibly including overnight stays, so that doctors and nurses can closely monitor you for any effects of the medicine and take blood samples to see how the medicine is moving through your body. There would also be follow-up appointments after you stop taking the medicine to ensure you are well. The total duration of your involvement could range from a few weeks to a couple of months, including the screening, dosing period, and follow-up.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is epilepsy?
Epilepsy is a condition that affects the brain and causes repeated seizures. Seizures are bursts of electrical activity in the brain that temporarily affect how the brain works.
What does 'Phase 1' mean for a study?
Phase 1 is the first time a new medicine is tested in people. The main goals are to check if it's safe and to understand how the body handles the medicine, not to treat a condition yet.
Will PTI5803 cure my epilepsy?
This study is not designed to treat or cure epilepsy. It's an early safety check to see if the medicine is safe enough to be tested in people with epilepsy in the future.
Who is funding this research?
The information provided doesn't state who is funding this specific trial. This is something the research team can tell you if you are interested in participating.
Can I continue with my normal activities during the study?
Depending on the study rules and how you feel, you might be asked to limit certain activities or stay at the clinic for periods. This will be fully explained before you agree to take part.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.